<abstract xmlns="http://www.w3.org/1999/xhtml">

Introduction: In most patients, metastatic breast cancer (MBC) is incurable. Consequently, the goal in this setting is life prolongation and quality of life improvement, although possible long-term effects of anticancer treatment need to be considered. Bone is the most common site of metastasis in breast cancer and its complex management includes minimizing the risk of skeletal-related events (SRE), maximizing pain control, stabilizing or even restoring function, preventing spinal cord compression, hypercalcemia of malignancy and fractures and reducing the need for radiotherapy and orthopedic surgery.
Aim: The present paper aims to compare the efficacy and safety of zoledronic acid (and other bisphosphonates) with denosumab in the management of bone metastases in breast cancer patients.
Materials and methods: In this article, required information was collected through literature review and keyword query using the PRISMA 2020 guideline.
Conclusions: In the metastatic setting, it appears that denosumab is indeed superior to zoledronic acid in delaying and preventing skeletal related events, except for spinal cord compression and risk of surgery, and equally efficient in treatment of already present bone pain and hypercalcemia of malignancy, with similar adverse effects, overall survival and disease progression.
</abstract>

Introduction: In most patients, metastatic breast cancer (MBC) is incurable. Consequently, the goal in this setting is life prolongation and quality of life improvement, although possible long-term effects of anticancer treatment need to be considered. Bone is the most common site of metastasis in breast cancer and its complex management includes minimizing the risk of skeletal-related events (SRE), maximizing pain control, stabilizing or even restoring function, preventing spinal cord compression, hypercalcemia of malignancy and fractures and reducing the need for radiotherapy and orthopedic surgery.
Aim: The present paper aims to compare the efficacy and safety of zoledronic acid (and other bisphosphonates) with denosumab in the management of bone metastases in breast cancer patients.
Materials and methods: In this article, required information was collected through literature review and keyword query using the PRISMA 2020 guideline.
Conclusions: In the metastatic setting, it appears that denosumab is indeed superior to zoledronic acid in delaying and preventing skeletal related events, except for spinal cord compression and risk of surgery, and equally efficient in treatment of already present bone pain and hypercalcemia of malignancy, with similar adverse effects, overall survival and disease progression.

The use of osteoclast inhibitors in metastatic breast cancer

“Elias” University Emergency Hospital

“Carol Davila” University of Medicine and Pharmacy

Orthopaedic Surgery and Traumatology Department

Romanian Journal of Orthopaedic Surgery and Traumatology

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

{"article-title":"The use of osteoclast inhibitors in metastatic breast cancer"}

Introduction: In most patients, metastatic breast cancer (MBC) is incurable. Consequently, the goal in this setting is life prolongation and quality of life...

The use of osteoclast inhibitors in metastatic breast cancer

Publié en ligne: 21 déc. 2022

Pages: 28 - 34

Accepté: 01 déc. 2022

DOI: https://doi.org/10.2478/rojost-2022-0006

Mots clés
metastatic breast cancer, osteoclast inhibitors, bisphosphonates, zoledronic acid, denosumab

© 2022 Cornelia Niţipir et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

The use of osteoclast inhibitors in metastatic breast cancer

Publié en ligne: 21 déc. 2022

Pages: 28 - 34

Accepté: 01 déc. 2022

DOI: https://doi.org/10.2478/rojost-2022-0006

Mots clésmetastatic breast cancer, osteoclast inhibitors, bisphosphonates, zoledronic acid, denosumab

© 2022 Cornelia Niţipir et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Mots clés
metastatic breast cancer, osteoclast inhibitors, bisphosphonates, zoledronic acid, denosumab